戻る Agenda
Session 7, Track C: Signal or Noise? Decoding the Pharmacovigilance Symphony
Session Chair(s)
Mei Lam, BSN, RN
Canada PV Manager/Safety Regional Country Contact
Haleon, Canada
Daniel Greco, PharmD, RPh
Associate Director of Patient Safety
Bristol-Myers Squibb Company, Canada
In the ever-evolving landscape of pharmacovigilance, distinguishing meaningful safety signals from background noise is crucial. This session, "Signal or Noise? Decoding the Pharmacovigilance Symphony," delves into the intricacies of assessing safety signals, emphasizing Health Canada's oversight approach. Participants will gain insights into practical tools and frameworks for identifying potential safety signals and explore future applications in signal detection and management.
Learning Objective : At the conclusion of this session, participants should be able to:- Understand Health Canada's approach to oversight in signal management
- To apply tools/framework to identify a potential safety signal
- To understand future applications to signal detection and management (TBD)
Speaker(s)
Social Media Safety Monitoring. Emergence of a New Global Tool for Early Signal Detection? Experience from the COVID-19 Vaccine
Heather Ward, PhD, MS
Pfizer, Canada
Director, Safety Surveillance Research
Aspects to Consider in Causality Assessment of Safety Signals: Broadening the Thought Process
Salman Afsar, MD, MHA
Bristol-Myers Squibb Company, United States
Senior Director and Signal Management Team Chair
Pharmacovigilance Signal Management: From Detection to Risk Mitigation
David Duguay, PhD
Health Canada , Canada
Pharmacovigilance Scientific Manager, Marketed Pharmaceuticals Bureau at MHPD